The device(s) you use to access the eBook content must be authorized with an Adobe ID before you download the product otherwise it will fail to register correctly.
For further information see https://www.wildy.com/ebook-formats
Once the order is confirmed an automated e-mail will be sent to you to allow you to download the eBook.
All eBooks are supplied firm sale and cannot be returned. If you believe there is a fault with your eBook then contact us on ebooks@wildy.com and we will help in resolving the issue. This does not affect your statutory rights.
The principal purpose of this book is to tell the story of a medicine's journey through the regulatory system in the UK, from the definition of a medicine, through clinical trials, licensing, pharmacovigilance, litigation, marketing and funding.
While the UK's regulatory regime is the principal focus, the question of global access to medicines is addressed not only because of its political importance, but also because it is an issue which places the question of whether medicines are a private or a public good in particularly stark focus.
Two further specific challenges to the future of medicines regulation are examined separately: pharmacogenetics, or the genetic targeting of medicines to subgroups of patients, and the possibility of using medicines to enhance wellbeing or performance, rather than treat disease.
Throughout, the emphasis is upon the role of regulation in shaping and influencing the operation of the medicines industry, an issue which is of central importance to the promotion of public health and the fair and equitable distribution of healthcare resources.
.jpg?1680780797)
